Jeremy Rifkin on the Real Economic Crisis

The real reason for the economic crisis is the diminishing supply of oil and other fossil fuels. That’s the conclusion of Jeremy Rifkin, President of the Foundation on Economic Trends and advisor to the European Union for the past decade, who goes on to explain why he believes industrial civilisation is at a dangerous crossroads.

This is the first of Jeremy’s two exclusive interviews with Criticaleye. In the second, Leadership and the New Energy Revolution, Jeremy explores the business opportunity of a third industrial revolution based on the use of Internet Communication Technology to manage distributed renewable energies.




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
Elevating Human Potential: Th...

The rapid advancement of AI has sparked concerns about its impact on job security. While these concerns merit thoughtful consideration, this report by Criticaleye Partner Workday focuses on how AI can empower people, ra...

Click here to download this insight
Europe's AI Reckoning: Reinve...

Europe’s productivity challenge is growing and the clear root cause is underinvestment in technology. In this report, Criticaleye Partner Accenture explores the potential of artificial intelligence (AI) to bo...

Click here to download this insight
Are Women Leaders Driving our...

How are women leaders responding to disruption in today’s uncertain world? This report from Criticaleye Partner AlixPartners draws on insights from its latest Disruption Index to reveal that women in leadership ar...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 369




Experian Workday Accenture Google British Land Lightsource bp Salesforce Hitachi Solutions Rolls-Royce Eightfold AI FTSE Women Leaders Review Concentrix NatWest Group Royal London Group Redwood Bank LDC London Stock Exchange Group Amazon UK Worldpay Legal & General IBM Consulting Palo Alto Networks Drax Group plc Aldermore Group AlixPartners NATS E.ON UK GlaxoSmithKline plc